Drugs / BMS-981164
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01614756 | Jul 2012 → Apr 2015 | atopic eczema | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-981164 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01614756 ↗ |
| Modality | Monoclonal antibody | “IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody; BMS-981164)” NCT01614756 ↗ |
| Route | Subcutaneous | “Single dose of BMS-981164 0.1 mg/kg solution subcutaneously” NCT01614756 ↗ |